Suein Choi, MD, PhD is a Clinical Associate Professor in the Department of Pharmacology at The Catholic University of Korea and a board-certified clinical pharmacologist at Seoul St. Mary's Hospital. She serves as Head of the Division of Data Science at the Pharmacometrics Institute for Practical Education and Training (PIPET). Her research spans pharmacometrics, PBPK/QSP modeling, pharmacoepidemiology using large-scale national health databases, and computational drug development. She has extensive experience in population pharmacokinetic modeling, exposure-response analysis for novel therapeutics in hematologic malignancies, and real-world evidence generation.

Dr Zi Wang is a clinical pharmacist at Zhongshan Hospital, Fudan University, Shanghai, China. He obtained his PhD in 2020. His research focuses on antithrombotic therapy management, drug–drug interactions, and clinical pharmacokinetics in cardiovascular patients. He has conducted multiple prospective cohort studies integrating real-world data and pharmacokinetic measurements to evaluate exposure–response relationships of direct oral anticoagulants.

Jeong Ho Lee has been affiliated with Chungbuk National University Hospital since September 2022 and is currently undertaking a Ph.D. course in Pharmacology at ChungBuk National University Graduate School, Cheongju. He also holds a Medical Master’s degree in Clinical Pharmacology & Therapeutics from ChungBuk National University Graduate School and a Bachelor’s degree in Biomedicinal Technology from Dong-A University, Busan. Jeong Ho Lee has extensive experience in clinical trials, primarily Phase I studies across a broad range of therapeutic areas. His research involvement includes studies in hypertension, type II diabetes mellitus, obesity, gastrointestinal disorders, dyslipidaemia, breast cancer, psoriasis, inflammatory bowel disease, chronic inflammatory demyelinating polyneuropathy (CIDP), infections, pain management, and respiratory conditions. He has also participated in bioequivalence studies for essential hypertension and studies relating to overactive bladder and benign prostatic hyperplasia. His clinical research experience reflects a strong focus on pharmacology and early-phase therapeutic development.

Ivana Čegec, MD, is a specialist in Clinical Pharmacology and Toxicology at the University Hospital Centre Zagreb. She graduated from the School of Medicine, University of Zagreb, in 2007 and completed her internship at UHC Zagreb. After working in outpatient clinical practice, she began her specialization in clinical pharmacology and toxicology in 2010 and passed the specialist examination with distinction in 2014. She is continuously employed at the Department of Clinical Pharmacology, where she works in inpatient care, day hospital services, outpatient clinics, and multidisciplinary consultations. Her professional focus includes rational pharmacotherapy, drug hypersensitivity diagnostics and testing, pharmacovigilance, antimicrobial stewardship, and patient safety. Dr. Čegec actively participates in clinical trials, development of national antimicrobial guidelines, and editorial work for professional journals. She is currently pursuing a PhD in Biomedicine and Health Sciences.

Dr. Andrej Belančić is a 32-year-old Specialist in Clinical Pharmacology at the Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Croatia. He also holds the academic title of Lecturer at the Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Croatia. In 2024, he received the Best Young Scientist award from the Faculty of Medicine, University of Rijeka, and in 2025 was named the best scientist in Croatia under the age of 40 by the Croatian Medical Chamber. Dr. Belančić is the author or co-author of more than 150 scientific and professional full-text articles and approximately 200 scientific abstracts. His scientific activities primarily focus on clinical pharmacology, rare diseases, obesity, and associated metabolic diseases. He is a Co-chair of the Early Career Clinical Pharmacologists Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT).

Sally Babiker is a second-year PhD student in the Clinical Pharmacology and Therapeutics Group at University College London, School of Pharmacy. Her research focuses on the optimisation of drug dosing in paediatric populations. In particular, her doctoral research investigates pharmacokinetic-pharmacodynamic relationships and dose rationale for antitubercular drug combinations in children with pulmonary and extrapulmonary tuberculosis, with the aim of improving treatment efficacy and supporting safer, shorter treatment regimens. Her broader research interests include model-informed drug development, paediatric clinical pharmacology, and quantitative approaches to dose optimisation across therapeutic areas, including chronic kidney disease. Prior to commencing her PhD, Sally obtained a BSc in Biomedical Sciences from King’s College London and an MSc in Clinical Drug Development from University College London.